Applicant: David Alland et al. Serial No.: 09/918,951 : July 31, 2001 Filed Page 2 IN THE SPECIFICATION: √Page 5, line 24, after "Nucleotides 9048-9101", insert -- (SEQ ID NO:1) --. √Page 5, line 25, after "MYT13E10", insert -- (nucleotides 1-159 of SEQ ID NO:2) -Page 5, line 27, after "numbering from MTY13E10 iniB 160-1559", insert --(nucleotides 160-1559 of SEQ ID NO:2) --. √Page 5, line 27, after "iniA 1636-3558", insert -- (nucleotides 1636-3558 of SEQ ID NO:2) --. ✓ Page 5, line 27, after "iniC 3555-5036", insert -- (nucleotides 3555-5036 of SEQ ID NO:2) --. √Page 6, line 1, after "iniB", insert -- (SEQ ID NO:3) --. Page 6, line 2, after "iniA", insert -- (SEQ ID NO:4) --. Page 6, line 2, after "iniC", insert -- (SEQ ID NO:5) --. ✓Page 12, line 11, replace "enchanters" with -- enhancers --. √Page 16, line 8, after "5'-CCTCTGAAGGTTCCAGAATCGATAG-3", insert -- (SEQ) ID NO:6) --. Page 16, line 9, after "CCTCTGAAGGTTCCAGAATCGATAGCTCGAGT-3", insert --(SEQ ID NO:7) --. Page 16, line 10, after "5'-P-ACTCGAGCTATCGATTCTGGAACCTTCAGAGGTTT-3", insert -- (SEQ ID NO:8) --. ✓Page 18, line 9, after "GCGCTGGCGGGAGATCGTCAATG-3", insert -- (SEQ ID NO:9) --.

NO:10) -/.

Page 18, line 9, after "TGCGCAGTCGGGTCACAGGAGTCG-3", insert -- (SEQ ID

 $\sqrt{\text{Page }}$ 18, line 10, after "TCCCGCCGCCGAACACCTA-3", insert -- (SEQ ID NO:11) --.

Applicant: David Alland et al.

Filed

Serial No.: 09/918,951 : July 31, 2001

Page 3

Page 18, line 10, after "GGATCCGGCCGACCAGAGA-3", insert -- (SEQ ID NO:12)

Page 18, line 11, after "GGAGTACGGCCGCAAGGCTAAAAC-3", insert -- (SEQ ID NO:13)

√Page 18, line 12, after "CAGACCCCGATCCGAACTGAGACC-3", insert -- (SEQ ID NO:14) --.

Please insert at the end of the application pages 1-12 containing the Sequence Listing attached hereto as Appendix B.

IN THE CLAIMS:

Please cancel claims 1-45.

Please amend claim 46 to read as follows:

- 46. (Amended) A method of determining whether a drug or compound is effective against Mycobacterium tuberculosis comprising:
- (a) transforming a vector construct comprising the nucleotide sequence of the iniB promoter inserted into a plasmid into a mycobacterium;
 - (b) culturing the mycobacterium:
 - (c) treating the cultured cells with the drug; and
- (d) measuring induction of the iniB promoter, the presence of induction indicating the drug is effective against *Mycobacterium tuberculosis*.

Please add the following claims 48 - 51.

48. (New) The method of claim 46, wherein the mycobacterium is selected from the group consisting of Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium